The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 β-1,6-N-acetylglusaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas by St Hill, Catherine A et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Cancer
Open Access Research article
The high affinity selectin glycan ligand C2-O-sLex and mRNA 
transcripts of the core 2 β-1,6-N-acetylglusaminyltransferase 
(C2GnT1) gene are highly expressed in human colorectal 
adenocarcinomas
Catherine A St Hill*1, Mariya Farooqui1, Gregory Mitcheltree1, H 
Evin Gulbahce2, Jose Jessurun2, Qing Cao3 and Bruce Walcheck4
Address: 1Department of Veterinary Clinical Sciences, University of Minnesota, Room C339, Veterinary Medical Center, 1352 Boyd Avenue, St. 
Paul, MN 55108, USA, 2Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 
55455, USA, 3Biostatistics and Informatics Shared Resource, University of Minnesota, 420 Delaware, Minneapolis, MN 55455, USA and 
4Department of Veterinary and Biomedical Sciences, University of Minnesota, 1988 Fitch Avenue, St Paul, MN 55108, USA
Email: Catherine A St Hill* - sthil001@umn.edu; Mariya Farooqui - faroo001@umn.edu; Gregory Mitcheltree - mitc0120@umn.edu; H 
Evin Gulbahce - gulba001@umn.edu; Jose Jessurun - jessu001@umn.edu; Qing Cao - caox0075@umn.edu; 
Bruce Walcheck - walch003@umn.edu
* Corresponding author    
Abstract
Background: The metastasis of cancer cells and leukocyte extravasation into inflamed tissues
share common features. Specialized carbohydrates modified with sialyl Lewis x (sLex) antigens on
leukocyte membranes are ligands for selectin adhesion molecules on activated vascular endothelial
cells at inflammatory sites. The activity of the enzyme core 2 β1,6 N-acetylglucosaminyltransferase
(C2GnT1) in leukocytes greatly increases their ability to bind to endothelial selectins. C2GnT1 is
essential for the synthesis of core 2-branched O-linked carbohydrates terminated with sLex (C2-
O-sLex). Our goal was to determine the expression profiles of C2-O-sLex in the malignant
progression and metastasis of colorectal adenocarcinomas. The well characterized CHO-131
monoclonal antibody (mAb) specifically recognizes C2-O-sLex present in human leukocytes and
carcinoma cells. Using CHO-131 mAb, we investigated whether C2-O-sLex was present in 113
human primary colorectal adenocarcinomas, 10 colorectal adenomas, 46 metastatic liver tumors,
28 normal colorectal tissues, and 5 normal liver tissues by immunohistochemistry. We also
examined mRNA levels of the enzyme core 2 β1,6-N-acetylglucosaminyltransferase (C2GnT1) in
20 well, 15 moderately, and 2 poorly differentiated colorectal adenocarcinomas, and in 5 normal
colorectal tissues by using quantitative real-time polymerase chain reactions (RT-PCR).
Results: We observed high reactivity with CHO-131 mAb in approximately 70% of colorectal
carcinomas and 87% of metastatic liver tumors but a lack of reactivity in colorectal adenomas and
normal colonic and liver tissues. Positive reactivity with CHO-131 mAb was very prominent in
neoplastic colorectal glands of well to moderately differentiated adenocarcinomas. The most
intense staining with CHO-131 mAb was observed at the advancing edge of tumors with the
deepest invasive components.
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Finally, we analyzed C2GnT1 mRNA levels in 37 colorectal adenocarcinomas and 5 normal
colorectal tissues by RT-PCR. Significantly, we observed a greater than 15-fold increase in C2GnT1
mRNA levels in colorectal adenocarcinomas compared to normal colorectal tissues.
Conclusion: C2-O-sLex, detected by the CHO-131 mAb, is a tumor associated antigen whose
expression is highly upregulated in colorectal adenocarcinomas and metastatic liver tumors
compared to normal tissues. C2-O-sLex is a potentially useful early predictor of metastasis.
Background
The malignant transformation of cells is associated with
abnormal glycosylation, which results in the altered
expression of carbohydrates on the surface of cancer cells
[1]. Aberrant glycosylation profoundly impacts most, if
not all processes involved in tumor cell invasion and
metastasis. The glycosylation status of specific carbohy-
drate epitopes can modulate diverse cellular functions
such as cell growth, adhesion, signal transduction, and
motility. Human carcinomas express high levels of the sia-
lyl Lewis x (sLex) tetrasaccharide, a sialylated and fuco-
sylated carbohydrate antigen, and its isomer sialyl Lea,
which are associated with a greatly increased metastatic
potential and a poor prognosis [2-7]. In particular, carbo-
hydrate antigens such as sLex are thought to contribute to
the metastatic process because sLex levels increase as color-
ectal adenocarcinomas progress from non-metastatic to
metastatic tumors [3,8]. The status of sLex, but not sLea, in
colorectal cancers was shown to be an independent pre-
dictive factor for disease recurrence, depth of tumor inva-
sion, and histologic type [9,10].
The sLex carbohydrate antigen can act as a ligand for the
selectin family of adhesion molecules [11,12]. Studies using
transfected cell lines [13-15] and knock out mice [16,17]
revealed that selectin binding to sLex is greatly increased
upon expression of the enzyme core 2 β1,6-N-acetylglu-
cosaminyltransferase (C2GnT1). C2GnT1 catalyzes the syn-
thesis of core 2 β1,6 branched O-glycans (C2-O-sLex). O-
glycosylation is initiated by tissue-specific addition of the N-
acetylgalactosamine (GalNAc) residue to a serine or threo-
nine of a protein. In subsequent enzymatic steps, the enzyme
C2GnT1 adds a β1,6 branched linkage of GlcNAc to a core 1
O-glycan scaffold to form the core 2 β1,6 branched structure.
The core 2 branch can be further extended by lactosamine
units and eventually terminated by sialylation (α2,3-sialyl-
transferase) and fucosylation [α-(1,3)-fucosyltransferase] to
form the sLex epitope, ultimately resulting in the synthesis of
C2-O-sLex [18] (Figure 1).
C2-O-sLex decorates the human leukocyte mucin P-selec-
tin glycoprotein ligand-1 (PSGL1, CD162) and confers
high affinity binding of PSGL-1 to the selectins [19,20], a
mechanism that is crucial for leukocyte migration during
inflammatory events. Much stronger bonds are formed
when leukocytes expressing cell surface C2-O-sLex bind to
selectins than when sLex is present on other glycans. Evi-
dence suggests that similar adhesion events may also
occur in the dissemination of tumor cells via the circula-
tory system [21-24]. In vitro and in vivo studies have dem-
onstrated that carbohydrate determinants, such as sLex, on
carcinoma cells are glycan ligands for the selectins [25-
29]. Interactions of L-selectin on leukocytes [30], E- and P-
selectin on the vascular endothelium [31-33], and P-selec-
tin on platelets [34] with their ligands have been impli-
cated to facilitate the metastasis of carcinoma cells. Thus
far, however, the importance of C2-O-sLeX in the progres-
sion and metastasis of colorectal carcinomas has not been
directly examined. As with leukocytes, the expression of
C2-O-sLex  on carcinoma cells may confer greatly
enhanced adhesion to the selectins and promote adher-
ence, extravasation, and metastasis.
Previous studies have reported that C2GnT1 transcripts,
and in some instances sLex, were expressed in carcinomas
and correlated with vessel invasion, depth of tumor inva-
sion, and metastasis [3,35-37]. These studies provided indi-
rect evidence that C2-O-sLex may participate in carcinoma
progression but this relationship needs to be confirmed by
the direct detection of C2-O-sLex on carcinoma cells. Detec-
tion of cell surface C2-O-sLex directly demonstrates the
functional activity of C2GnT1. This distinction is important
because other enzymes can compete with C2GnT1 and pre-
vent the formation of C2-O-sLex in carcinoma cells [38].
Inhibition of C2GnT1 by other enzymes can result in the
distribution of sLex on other carbohydrates, including O-
glycans, N-glycans and glycolipids, that may have much
lower affinities for selecting binding [39].
Recently, we have extensively characterized the mono-
clonal antibody (mAb) CHO-131 that specifically recog-
nizes C2-O-sLex [40]. The binding specificity of CHO-131
mAb was evaluated using synthetic glycopeptides mod-
eled after the N-terminus of human PSGL-1 containing
precise O-glycan structures [40]. The reactivity of CHO-
131 mAb, unlike that of anti-sLex antibodies, requires the
functional activity of the glycosyltransferases C2GnT1,
α2,3-sialyltransferase, and α1,3-fucosyltransferase and
therefore was ideal for addressing our hypothesis [40-42].
CHO-131 mAb is not a function blocking antibody, how-
ever, and at high concentrations does not inhibit interac-
tions of leukocyte C2-O-sLex on PSGL1 with P-selectinBMC Cancer 2009, 9:79 http://www.biomedcentral.com/1471-2407/9/79
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[40]. We have previously demonstrated that C2-O-sLex
was expressed on a colorectal adenocarcinoma cell line
that avidly attached to E-selectin [43]. The purpose of this
study was to investigate the expression of C2-O-sLex in
malignant and benign human colorectal tissues and
hepatic metastases. We hypothesized that C2-O-sLex, a
high affinity selectin ligand, is abundantly expressed on
carcinoma cells and is associated with malignant progres-
sion and metastasis of colorectal adenocarcinomas. In our
approach, we used RT-PCR and immunohistochemistry to
assess the levels of C2GnT1 mRNA and expression of C2-
O-sLex in colorectal adenocarcinomas, adenomas, meta-
static liver tumors and normal colorectal and liver tissues.
We found higher expression of C2-O-sLex  and corre-
spondingly high C2GnT1 mRNA levels on colorectal ade-
nocarcinomas compared to normal tissues. We also
observed high expression of C2-O-sLex on liver metastases
of colorectal adenocarcinomas. Based on these results, we
propose that C2-O-sLex is a tumor associated antigen and
a potential predictor of tumor progression and metastasis.
Methods
Tissue Samples
All tissues were used in accordance with the University of
Minnesota's Institutional Review Board regulations. For
the immunohistochemical staining procedures tissue
samples were from males and females between the ages of
26 and 82 years. The tissue samples used for the RT-PCR
analysis were from males and females between the ages of
31 and 93 years.
Antibodies
CHO-131 mAb is a mouse IgM that binds the glycan struc-
ture C2-O-sLex and specifically recognizes the presence of
this glycan in human leukocytes and carcinoma cells
[40,43]. Mouse anti-CEA clone Col-1 mAb is a mouse
IgG2a (Invitrogen, Carlsbad, CA) that specifically recog-
nizes human carcinoembryonic antigen (CEA) in the
cytoplasm and membrane of colorectal adenocarcinoma
cells but does not react with normal colorectal tissues or
with non-specific cross-reacting antigen. Pre-malignant
cells, such as colorectal adenomas, also positively react
with anti-CEA mAb. Mouse mAb Ab-3, clone Lu-5 is a
mouse IgG1 (Thermo Fisher Scientific, Fremont, CA) and
is a broad spectrum anti pan-keratin antibody which
reacts with epithelial cells and differentiates epithelial
from non-epithelial tumors. CSLEX 1 mAb, obtained
from Dr. Bruce Walcheck, is a mouse IgM that recognizes
the sLex epitope on the cell membrane.
The secondary antibodies used for CSLEX1 and CHO-131
mAb staining were mu-chain specific horseradish peroxi-
dase (HRP) conjugated goat anti-mouse IgM (Invitrogen,
Carlsbad, CA) and mu-chain specific alkaline phos-
phatase (AP) conjugated goat anti-mouse IgM (Chemicon
International Inc., Billerica, MA) respectively. For Lu-5
and CEA staining, gamma-chain specific horseradish per-
oxidase conjugated goat anti-mouse IgG (Chemicon
International Inc., Billerica, MA) was used as a secondary
antibody. Mouse IgM, mouse IgG2a and mouse IgG1 (Inv-
itrogen) were used as negative control antibodies for
CHO-131, CEA, and Lu-5 mAb staining respectively at the
same concentrations as the corresponding primary anti-
bodies.
Histopathology
Tissue sections used for immunohistochemical staining
were 4-μm thickness, fixed in 10% neutral buffered for-
malin, and embedded in paraffin. We stained representa-
tive sections from each case with hematoxylin and eosin
(H & E) according to standard procedures to evaluate tis-
sue morphology. We examined 113 cases of primary
colorectal adenocarcinomas, 46 cases of liver metastasis of
colorectal adenocarcinomas, 10 cases of colorectal adeno-
mas, 28 normal colorectal tissues, and 5 normal liver sam-
ples from pooled specimens that were obtained
commercially from MaxArray colorectal adenocarcinoma/
normal tissue microarrays (Invitrogen, Carlsbad, CA);
AccuMax colon cancer and liver metastasis of colon cancer
arrays (ISU ABXIS Co., Ltd, Seoul, South Korea); and from
archived tissues (Tissue Procurement Facility, University
Diagram of core 2 β1,6 O-glycan synthesis Figure 1
Diagram of core 2 β1,6 O-glycan synthesis. (A) Core 1 
O-glycans are synthesized by addition of β1,3 galactose to N-
acetylgalactosamine. (B) The C2GnT1 enzyme converts an 
unsubstituted core 1 O-glycan to a core 2 β1,6 O-glycan. (C) 
Core 2 can be further modified by α2,3 sialyltransferase and 
α1,3 fucosyltransferase, forming a sLex terminus (dotted 
box). These modifications result in the synthesis of the sLex-
modified core 2 β1,6 O-glycan (C2-O-sLex) structure. The 
figure is simplified and some enzymatic steps are omitted for 
clarity. GalNAc, N-acetylgalactosamine; Gal, galactose; Glc-
NAc, N-acetylglucosamine; NeuAc, sialic acid; Fuc, fucose.
sLe
x-modified core 2 E1,6 O-glycan (C2-O-sLe
x)BMC Cancer 2009, 9:79 http://www.biomedcentral.com/1471-2407/9/79
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of Minnesota, Minneapolis, MN). Serial sections were pre-
pared from tissues stained with CHO-131 mAb of 113
colorectal adenocarcinomas, 38 metastatic liver tumors, 5
sections of normal colonic mucosa, and 5 sections of nor-
mal liver, and were stained with CSLEX1 mAb. An addi-
tional 21 primary colorectal adenocarcinomas (134 total
adenocarcinomas) were stained with CSLEX1 mAb to ver-
ify localization of the sLex epitope.
A TissueScan colon cancer tissue qPCR array panel (Ori-
gene Technologies, Rockville, MD) was obtained com-
mercially and used for evaluation of mRNA expression of
C2GNT1 in colorectal tissues by RT-PCR. The panel con-
sisted of cDNAs from tissue samples of 42 human color-
ectal adenocarcinomas and 6 normal colorectal tissues
that were PCR-ready and normalized with β-actin by the
company.
Tissues used in the immunohistochemical staining proce-
dures and those from which mRNA was isolated for the
quantitative real time-PCR (RT-PCR) experiments were
classified as grades of well differentiated, moderately dif-
ferentiated, and poorly differentiated that represented the
differentiation status of tumor cells.
Immunohistochemistry
Tumor sections for all staining procedures were deparaffi-
nized in three changes of xylene, hydrated through 100-
70% graded concentrations of ethanol and washed in dis-
tilled water and 1× Tris/Tween buffer, pH 7.6. To elimi-
nate non-specific staining, tissue sections were incubated
with protein block (ScyTek Laboratories, Logan, UT) for
10 minutes, excess block was removed and primary anti-
body was immediately applied to sections. Incubations
with protein block and primary and secondary antibodies
were carried out in a humidified chamber at 27 – 30°C.
The remaining staining procedures were performed at
room temperature. As negative controls, additional sec-
tions from each specimen were prepared by replacing the
primary antibody with the corresponding isotype-
matched, negative control antibody (Invitrogen,
Carlsbad, CA) using similar conditions and antibody con-
centrations to determine the specificity of antibody bind-
ing. The primary antibody was removed by washing in 1×
Tris/Tween buffer and secondary antibody was applied to
tissue sections. Sections were washed, incubated with the
chromagen, and counterstained with Mayer's hematoxy-
lin (Dako, Carpinteria, CA). Sections were washed, dehy-
drated through 70 – 100% graded alcohols, 100%
xylenes, and mounted. Stained sections were evaluated by
light microscopy.
To detect C2-O-sLex, tissue sections were stained with
CHO-131 mAb at a concentration of 15 μg/ml. It was not
necessary to perform antigen retrieval or blocking of
endogenous peroxidase activity. CHO-131 mAb was
applied to tissue sections for 2 hours. Sections were
washed and incubated with mu-chain specific goat anti-
mouse IgM-AP secondary antibody (16 μg/ml) for 30
minutes. After washing, tissue sections were incubated
with a Vector Red alkaline phosphatase chromagen (Vec-
tor Laboratories, Burlingame, CA) for 2 minutes.
For detection of the sLex epitope, antigen retrieval was not
performed. Endogenous peroxidase activity was blocked
by incubation of sections with 3% hydrogen peroxide in
1× PBS for 15 minutes at room temperature. Tissue sec-
tions were stained with CSLEX1 mAb (15 μg/ml) for 2
hours, washed, and incubated with mμ-chain specific goat
anti-mouse IgM-HRP (30 μg/ml) antibody for 30 min-
utes. Sections were washed and 3,3- diaminobenzidinetet-
rahydrochloride (DAB) chromagen (Vector Laboratories,
Burlingame, CA) was applied for 5 minutes.
The HL-60 promyelocytic leukemia cell line (American
Type Culture Collection, Manassas, VA) expresses high
levels of membrane bound sLex, high C2GnT1 activity
[44], and in our hands expressed high levels of C2-O-sLex.
Cytospins of HL-60 cells (3 × 104 cells/sample) were gen-
erated using a Shandon-Southern SCA-0031 cytocentri-
fuge (Sewickley, PA, USA) at a speed of 1000 rpm for 5
minutes and were stained with CSLEX1 and CHO-131
mAbs as positive controls.
As additional positive controls, mouse anti-CEA mAb was
used at a concentration of 1.6 μg/ml. Lu-5 mAb was used
at a concentration of 0.5 μg/ml. The anti-CEA and Lu-5
mAb staining techniques were performed similarly to that
for CSLEX1 mAb with some modifications. Proteinase K
(Dako, Carpinteria, CA) was used for antigen retrieval in
the Lu-5 but not in the CEA mAb staining procedures
according to the manufacturer's instructions. Endogenous
peroxidase activity was blocked in both Lu-5 and CEA
mAb staining techniques. Tissue sections were incubated
with either Lu-5 mAb for 30 minutes or anti-CEA mAb for
60 minutes. Sections were washed and incubated with
gamma-chain specific goat anti-mouse IgG-HRP antibody
(16 μg/ml) of for 30 minutes. After washing, sections were
stained with DAB chromagen for 5 minutes.
Quantitative Real Time-PCR
Specific primers for C2GNT1 (Gen Bank Accession
number NM_001490) were designed as follows: the for-
ward primer was 5'-GAT GTC ACC TGG AAT CAG CA-3'
and the reverse primer was 5'-GCA GCA ACG TCC TCA
GCA T-3'. The cDNAs were amplified in an Applied Bio-
systems 7500 Real-Time PCR system using a reaction vol-
ume of 7.5 μl containing 1× SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA) and 15 pmol/μL of
each primer. The PCR conditions included one cycle atBMC Cancer 2009, 9:79 http://www.biomedcentral.com/1471-2407/9/79
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95°C for 10 minutes followed by 50 cycles of denatura-
tion at 95°C for 15 seconds; annealing at 58°C for 23 sec-
onds; and extension at 72°C for 35 seconds. The
dissociation was performed in cycles of 95°C for 15 sec-
onds; annealing at 60°C for 60 seconds; and extension at
95°C for 15 seconds. The relative amount of C2GNT1
transcripts in each sample was normalized to the house
keeping gene β-actin by removing the cycle threshold (Ct)
value of β-actin from Ct value of C2GNT1 (ΔCt). The fold
difference was calculated by subtracting the ΔCt of the test
sample from that of the control sample to give ΔΔCt, and
fold difference = 2-ΔΔCt [45]. Absolute transcript expres-
sion values for C2GNT1 and β-actin beyond 45 cycles
were considered to be below detectable levels and those
data were eliminated. Each assay was done in duplicate
and melt curves were conducted for each reaction to guar-
antee that a single product was amplified. The PCR prod-
ucts were further confirmed by gel electrophoresis.
Histologic and RT-PCR Grading System for Tissues
The intensity of CHO-131 mAb staining for C2-O-sLex in
immunoreactive tissues was scored using a semiquantita-
tive system from 0+ to 3+. Score 0+, no visible immunos-
taining; score 1+, mild immunostaining; score 2+,
moderate immunostaining; and score 3+, strong immu-
nostaining. A score of 0+ to 1+ indicated low reactivity
with CHO-131 mAb and a score of 2+ to 3+ indicated
high reactivity. Cells were evaluated in five different high-
power field areas for each tissue section. Each tissue spec-
imen was scored independently by two pathologists. Any
discordant scores were re-evaluated and scored again on
the basis of a consensus opinion.
Statistical Analysis
All statistical analyses were implemented using SAS statis-
tical software, version 9.1. In all statistical tests, a p-value
of ≤ 0.05 was considered significant. For analysis of the
expression of C2-O-sLex  in tissue sections of primary
colorectal adenocarcinomas and those carcinomas meta-
static to the liver, (as indicated by CHO-131 mAb stain-
ing), tissues were grouped as either well, moderately, or
poorly differentiated. Malignant tissues were also catego-
rized as low expression (score 0+ to 1+) and high expres-
sion (score 2+ to 3+) for C2-O-sLex. The Pearson's chi-
square test was applied to groups to test any associations
between the categorical variables and odds ratios were cal-
culated by the methods of Cochran, Mantel, and Haen-
szel. The levels of C2GnT1 mRNA in normal colorectal
tissues and in well, moderately, and poorly differentiated
colorectal adenocarcinomas, but not in liver tissues, was
analyzed using the Kruskal-Wallis test with a 5% signifi-
cance level. The subgroup comparisons between the well,
moderate, and poor groups with the normal group were
adjusted by the Bonferroni method.
Results
C2-O-sLex was detected in colorectal adenocarcinomas 
and metastatic liver tumors by immunohistochemistry
There was a unique pattern of reactivity with CHO-131
mAb in cancer tissues. CHO-131 mAb positively stained
both the cytoplasm and luminal surfaces of glandular
structures in all colorectal adenocarcinomas. The intramu-
cosal aspects of each adenocarcinoma stained less
intensely with the CHO-131 mAb and the staining pattern
was irregular. The deeper submucosal and muscularis
areas of intestine that were infiltrated by tumor cells dem-
onstrated a more uniform, intense staining for CHO-131
mAb and this finding was especially prominent at the
advancing edge of the tumor with the deepest invasive
components (Figure 2A, B). The positive reactivity with
CHO-131 mAb was most prominent in neoplastic color-
ectal glands of well to moderately differentiated colorectal
adenocarcinomas (Figure 2C, D and Figure 3A).
As colorectal adenocarcinomas progressed from a well to
poorly differentiated status, proportionately greater num-
bers of carcinomas displayed increased areas of solid
tumor growth that lacked glandular structures. Eight of 8
poorly differentiated colorectal adenocarcinomas exam-
ined demonstrated positive reactivity with CHO-131
mAb. We detected high (2+ to 3+) positive staining in 6 of
8 of these tissues. In two of these 6 positively stained,
poorly differentiated adenocarcinomas approximately
95% of the tumor consisted of glandular structures that
were highly reactive (3+ intensity) with CHO-131 mAb.
An example is shown in Figure 3B. In the remaining 4
poorly differentiated adenocarcinomas, only 5–20% of
the neoplastic tissue consisted of glandular structures that
were highly reactive with CHO-131 mAb. Instead, the
majority of the tumor consisted of non-reactive fibrous
tissue. Lastly, we observed low (1+) reactivity with CHO-
131 mAb in the remaining 2 of 8 poorly differentiated
colorectal adenocarcinomas with minimal glandular
structures (less than 10% of the total tumor). Glandular
structures in normal colorectal epithelium and in colorec-
tal adenomas did not react with CHO-131 mAb (Figure 2E
and Figure 3C, D, E).
In our positive controls, we observed that between 75 –
100% of the total tumor area in all colorectal adenocarci-
nomas stained positively with the anti-CEA mAb, regard-
less of differentiation status. In colorectal
adenocarcinomas, reactivity with anti-CEA mAb was
localized to the luminal and sub-membranous regions of
the cytoplasm and the staining pattern mimicked that of
CHO-131 mAb staining (Figure 2F). As expected, all
colorectal adenomas showed positive reactivity with the
anti-CEA mAb in 25 – 50% of the total area of each tissue.
A representative colorectal adenoma stained with anti-
CEA mAb is shown in Figure 3F. Serial tissue sections ofBMC Cancer 2009, 9:79 http://www.biomedcentral.com/1471-2407/9/79
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liver metastases of primary colorectal adenocarcinomas
that reacted positively with CHO-131 mAb displayed
strong positive reactivity with the anti-CEA mAb in similar
areas of tissue. In contrast, anti-CEA mAb did not react
with normal liver tissues (data not shown). As expected,
we observed positive reactivity with the Lu-5 mAb in all
normal and malignant colorectal and liver tissues exam-
ined (data not shown). In HL-60 cells used as positive
controls, the cell membrane and cytoplasm stained
strongly (3+ reactivity) with the CHO-131 mAb (data not
shown). All tissue specimens stained with isotype
matched negative control antibodies were negative for tis-
sue reactivity.
A summary of the reactivity of colorectal adenocarcino-
mas with CHO-131 mAb is shown in Table 1. Of the 113
total colorectal adenocarcinomas examined, 22 were well
differentiated, 83 were moderately differentiated, and 8
were poorly differentiated. We observed high, (2+ to 3+),
positive reactivity with the CHO-131 mAb in 50% (11 of
22) well differentiated, 72% (60 of 83) moderately differ-
entiated, and 75% (6 of 8) poorly differentiated adenocar-
cinomas. Colorectal adenocarcinomas in the moderately
differentiated group displayed significantly higher levels
of positive CHO-131 mAb staining compared to those
adenocarcinomas in the well differentiated group (Pear-
son's chi-squared test, p-value = 0.04, odds ratio = 0.38)
(Figure 4A). Although the majority of poorly differenti-
ated adenocarcinomas examined reacted positively with
CHO-131 mAb at high (2+ to 3+) intensity, significant
differences in reactivity were not observed when poorly
differentiated colorectal adenocarcinomas were compared
with the well and moderately differentiated groups.
Colorectal adenocarcinomas metastatic to the liver but
not normal liver tissues were positively reactive with the
CHO-131 mAb. CHO-131 mAb staining was detected in
the cytoplasm and at the surfaces of glandular lumens of
neoplastic cells. Of the 46 well, moderately and poorly
differentiated metastatic liver tumors examined, 40 were
positively stained with CHO-131 mAb and 35 were
strongly positive (2+ to 3+ staining) (Table 2).
We assessed whether the reactivity of CHO-131 mAb and
CSLEX1 mAb overlapped. All primary colorectal adeno-
carcinomas and metastatic liver tumors examined reacted
positively with CSLEX1 mAb. The percentage of colorectal
adenocarcinomas that were highly reactive with CHO-131
mAb (2+ to 3+ staining intensity) are shown in Figure 4B.
The cytoplasm of glandular structures in primary colorec-
tal adenocarcinomas and metastatic tumors was positively
stained with CSLEX1 mAb and reactivity was not related
to differentiation status of the tumor. We observed strong,
highly positive 2+ to 3+ reactivity with CSLEX1 mAb in
similar tissue locations of colorectal adenocarcinomas
and metastatic liver tumors to those areas that positively
reacted with CHO-131 mAb (Figure 5A, B, C, D and Table
3). However, positive staining with CSLEX1 mAb was
more widely distributed in tissues than that with CHO-
131 mAb. Normal colonic mucosa and hepatocytes in
normal liver lacked reactivity with CSLEX1 mAb (Figure
Human well differentiated colorectal adenocarcinomas  expressed low levels of C2-O-sLex Figure 2
Human well differentiated colorectal adenocarcino-
mas expressed low levels of C2-O-sLex. (A) Photomi-
crograph of a tissue section of a well differentiated colorectal 
adenocarcinoma stained with hematoxylin and eosin, scale 
bar = 500 μm. (B) A serial section of the same tissue as 
shown in (A) stained with CHO-131 mAb (15 μg/ml). Red 
color indicates positive reactivity with the CHO-131 mAb, 
scale bar = 500 μm. In (A) and (B) the arrow indicates adja-
cent normal colorectal mucosa. The arrowhead indicates 
nests of neoplastic cells in the tunica submucosa and muscu-
laris. (C) Another well differentiated colorectal adenocarci-
noma stained with CHO-131 mAb. Red color indicates 
positive reactivity with the CHO-131 mAb, scale bar = 100 
μm. (D) Increased magnification of the boxed area shown in 
(C) demonstrating red stained CHO-131+ cells. Arrows in 
(D) indicate cytoplasmic and luminal reactivity with CHO-
131 mAb, scale bar = 50 μm. (E) Mucosa of normal colorec-
tal epithelium stained with CHO-131 mAb. Note the absence 
of red color, indicating a lack of reactivity with the CHO-131 
mAb, scale bar = 150 μm. (F) A serial section of the same tis-
sue as in (C) and (D), stained with CEA mAb (1.6 μg/ml). 
Brown color indicates positive reactivity with CEA mAb, 
scale bar = 100 μm. All tissue sections were 4 μm thickness. 
Figures (A) and (B) 20× magnification, (C) 200× magnifica-
tion, (D) 400× magnification, (E) 100× magnification, and (F) 
200× magnification. Mayer's hematoxylin was used as a coun-
terstain for tissues stained with CHO-131 and CEA mAbs. 
Representative sections from multiple stained tissues are 
shown.
A B
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5E, F). Representative sections of metastatic liver tumors
that were positively stained with CHO-131 mAb are
shown in Figure 6.
C2GnT1 mRNA levels were upregulated in colorectal 
adenocarcinomas
We used RT-PCR to analyze C2GnT1 mRNA levels in 20
well, 15 moderately, and 2 poorly differentiated colorectal
adenocarcinomas and we compared these mRNA expres-
sion levels to those in 5 normal colorectal tissues. The
amplification plot from the RT-PCR assay is shown in Fig-
ure 7A. As shown in Figure 7B, C2GnT1 mRNA levels were
more than 15 times higher in the well and moderately dif-
ferentiated colorectal adenocarcinomas when compared
to normal colorectal tissues, and this difference was statis-
tically significant (p = 0.015 and p = 0.025 respectively
using the Kruskal-Wallis test). Although C2GnT1 mRNA
levels were more than 9-fold upregulated in poorly differ-
entiated colorectal adenocarcinomas compared to normal
colorectal tissues, the change was not significant.
Discussion
The C2-O-sLex motif on leukocytes confers much higher
affinity binding to the selectins than sLex [19,20]. Detec-
tion of C2GnT1 mRNA transcripts, and in some instances
sLex, have been reported to positively correlate with the
invasiveness and metastasis of human colorectal, pulmo-
nary, and oral cavity carcinomas [35-37]. These studies
indirectly imply that C2-O-sLex  expression may be
increased on carcinoma cells. However, the presence of
the sLex  epitope on cells is not always indicative of
C2GnT1 gene expression because sLex can decorate other
glycoconjugates such as glycoproteins, glycolipids, N-gly-
cans and O-glycans [46-51], that may have different func-
tions from those of C2-O-sLex. The direct detection and
evaluation of C2-O-sLex in the progression and metastasis
of human colorectal adenocarcinomas has not been per-
formed. We hypothesized that C2-O-sLex – a cell surface
expressed high affinity selectin ligand – is expressed on
carcinoma cells and is associated with malignant progres-
sion and metastasis. Our hypothesis was based on evi-
dence suggesting that similar adhesion mechanisms
regulate extravasation of leukocytes and carcinoma cells
from the circulatory system into tissues [21-24].
The major findings of our study were that C2-O-sLex, a
glycan detected by the CHO-131 mAb, was abundantly
present in human colorectal adenocarcinomas and meta-
static liver tumors but was absent in colorectal adenomas
and normal colorectal and liver tissues. As colorectal ade-
nocarcinomas progressed from well to moderately differ-
entiated status, significantly greater numbers of the
tumors examined displayed high levels of C2-O-sLex on
the cell surface where more than 50% of the total tumor
mass was positive for C2-O-sLex expression. Furthermore,
we detected a significant increase (greater than 15-fold) in
average C2GnT1 mRNA levels in well and moderately dif-
ferentiated colorectal adenocarcinomas compared to nor-
mal colorectal tissues by RT-PCR. Our findings are novel
because, to our knowledge, we are the first to provide
direct evidence that C2-O-sLex on colorectal adenocarci-
nomas is a tumor antigen and that increased expression of
C2-O-sLex is associated with more advanced disease.
We detected high expression of C2-O-sLex in the majority
(6 of 8) of poorly differentiated adenocarcinomas. We
observed the highest C2-O-sLexexpression (3+ staining
Human colorectal adenocarcinomas, but not colorectal ade- nomas, expressed high levels of C2-O-sLex Figure 3
Human colorectal adenocarcinomas, but not color-
ectal adenomas, expressed high levels of C2-O-sLex. 
(A) Photomicrograph of a tissue section of a moderately dif-
ferentiated colorectal adenocarcinoma stained with CHO-
131 mAb (15 μg/ml). Red color indicates positive cytoplasmic 
and luminal reactivity with CHO-131 mAb. (B) A poorly dif-
ferentiated colorectal adenocarcinoma stained with CHO-
131 mAb. Notice the red color indicating positive cytoplas-
mic reactivity of neoplastic cells (arrow). (C) A colorectal 
adenoma stained with hematoxylin and eosin. (D) A serial 
section of the same tissue as in (C), stained with CHO-131 
mAb. Notice the absence of red color. (E) Mucosa of normal 
colorectal epithelium stained with CHO-131 mAb. (F) A 
serial section of the same tissue as in (C) and (D), stained 
with CEA mAb (1.6 μg/ml). The brown color indicates posi-
tive reactivity with CEA within the lumens of glands and in 
the cellular cytoplasm. All tissue sections were 4 μm thick-
ness; scale bars = 100 μm, 200× magnification. Mayer's hema-
toxylin was used as a counterstain for tissues stained with 
CHO-131 and CEA mAbs. Representative sections from 
multiple stained tissues are shown.
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intensity) in 2 of 6 malignant tissues where over 95% of
the tumor mass consisted of neoplastic glandular struc-
tures. We also found a 9-fold increase in C2GnT1 mRNA
levels in poorly differentiated adenocarcinomas com-
pared to normal colorectal tissues that was not statistically
significant. These results were surprising because we
expected poorly differentiated adenocarcinomas to have
the highest expression of cell surface C2-O-sLex and corre-
sponding upregulation of C2GnT1 mRNA. Poorly differ-
entiated colorectal adenocarcinomas account for 5–10%
of all cases of colorectal cancer and are regarded as highly
malignant. These tumors can be further classified into
solid type and non-solid type patterns of growth where
the solid type pattern is predominantly non-glandular.
We observed that C2-O-sLex expression is mainly local-
ized to neoplastic glands. In the majority (6 of 8) of the
poorly differentiated colorectal adenocarcinomas that we
examined there was minimal glandular differentiation
compared with well and moderately differentiated adeno-
carcinomas. This finding is a likely explanation for the
decrease in C2GnT1 mRNA expression and reactivity with
CHO-131 mAb that we observed in poorly differentiated
tumors. Because solid type poorly differentiated colorectal
adenocarcinomas are associated with a better prognosis
compared to the non-solid type [52], we speculate that the
intense reactivity with CHO-131 mAb that we observed in
highly glandular non-solid type poorly differentiated
colorectal adenocarcinomas is an indicator of a poor
prognosis. This possibility remains to be investigated in
the future using a larger sample size of this subgroup of
tissues. Another possible reason for the decrease in
C2GnT1 mRNA levels that we observed in poorly differen-
tiated colorectal adenocarcinomas is that the tissues used
for RT-PCR and those used for immunohistochemistry
were from different sources and we could not make a
direct correlation between C2GnT1 mRNA levels and C2-
O-sLex levels in the same patient. The small sample size
obtained for the poorly differentiated adenocarcinomas
used in the immunohistochemical staining (n = 8) and
RT-PCR analysis (n = 2) may be an additional explanation
for this discrepancy.
Intestinal mucins are glycoproteins characterized by dense
O-glycosylation on serine and threonine amino acids.
Colonic mucins have four main O-glycan core structures (1–
4). Of these structures, core 2 beta 1,6 branching is critical for
biosynthesis of sLex on O-glycans. Core 2 branching can be
synthesized by at least three enzymes in the C2GnT family,
C2GnT1 or C2Gnt-L (leukocyte-type) [53], C2GnT2 or
C2GnT-M (mucin-type) [54] and C2GnT3 or C2GnT-T (thy-
mus-associated) [54,55]. C2GnT-M can form multiple
branched structures: core 2 type branching, core 4 type
branching, and blood group antigen I. C2GnT-M is highly
expressed in healthy colonic mucosa and is replaced by
C2GnT-L in colon cancer tissues [56]. Recently, Huang et al.
reported that C2GnT-M is downregulated in colorectal can-
cer and suppresses colon cancer cell growth [57]. In this
study the differentiation status of the tumors was not exam-
ined. C2GnT-L and C2GnT-M may have distinct but overlap-
ping functions in the progression of colorectal carcinomas.
We observed a considerable increase in C2CnT-L expression
at the protein and mRNA levels as colorectal carcinomas pro-
gressed from well to moderately differentiated. We speculate
that in the early stages of colorectal cancer carcinogenesis,
C2GnT-M may predominate in colonic tissues with develop-
ing malignancy and act as a control mechanism to inhibit
the growth of colon cancer cells. As the tumor progresses to
more advanced stages, upregulated C2GnT-L activity may
predominate and be associated with a corresponding
increase in C2-O-sLex expression on colorectal cancer cells.
The biochemical pathway of C2-O-sLex synthesis is complex
involving several sequential glycosyltransferase reactions.
We cannot rule out that other glycosyltransferases in addi-
tion to C2GnT1 may also be upregulated in colorectal aden-
ocarcinomas resulting in the increased C2-O-sLex levels that
we observed in our study. Nevertheless, our findings indicate
that high levels of C2-O-sLex, detected by the CHO-131
mAb, corresponded to measurable upregulation of the
C2GnT1 gene as colorectal adenocarcinomas progressed in
malignancy.
C2-O-sLex is also present on most leukocytes but this cell
type was easily morphologically distinguishable from car-
Table 1: C2-O-sLex was expressed in human primary colorectal adenocarcinomas.
CHO-131 mAb staining reactivity in colorectal adenocarcinomas
Differentiation status 0+ 1+ 2+ 3+
Well differentiated 1 10 (5) 5 (4) 6 (5)
Moderately differentiated 13 10 (1) 28 (12) 32 (14)
Poorly differentiated 0 2 (0) 2 (0) 4 (2)
10 benign adenomas were negative for C2-O-sLex expression by CHO-131 staining. 28 normal tissues were negative for C2-O-sLex expression by 
CHO-131 staining. The brackets indicate the number of tissues where greater than 50% of the total tumor mass stained positively with CHO-131 
mAb.BMC Cancer 2009, 9:79 http://www.biomedcentral.com/1471-2407/9/79
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cinoma cells by hematoxylin and eosin staining. Further-
more, we performed immunohistochemical staining with
the Lu-5 mAb that detects epithelial cells to verify that C2-
O-sLex positive malignant cells were epithelial in origin.
Thus, we found that the C2-O-sLex antigen on colorectal
adenocarcinomas was associated with a more advanced
tumor. Similarly to leukocytes, C2-O-sLexmay represent a
high affinity glycan ligand for the selectins.
Providing direct evidence for the expression of C2-O-sLex
on carcinoma cells is important because this oligosaccha-
ride serves as a high affinity ligand for the selectins during
leukocyte migration into sites of inflammation and sec-
ondary lymphoid organs. Similarly, C2-O-sLex may func-
tion as a high affinity selectin ligand on carcinoma cells
that promotes adhesion of malignant cells to endothe-
lium and subsequent metastasis. The direct demonstra-
tion of C2-O-sLex on the cell surface is essential because
other enzymes such as the glycosyltransferase ST3 beta-
galactoside alpha-2,3-sialyltransferase 1 can compete with
C2GnT1 in carcinoma cells and inhibit the conversion of
core 1 O-glycans to core 2 [38].
It is well established that levels of sLex increase during pro-
gression of colorectal adenocarcinomas from nonmeta-
static to metastatic tumors and there is an inverse
correlation with postoperative survival [10]. However, a
direct investigation of the expression of C2-O-sLex specifi-
cally at various stages of malignant colorectal tumor
growth and in normal colorectal tissues had not been per-
formed previously. Similarly to leukocytes, expression of
C2-O-sLex may promote much greater selectin-mediated
adhesiveness of cancer cells to endothelium than sLex on
other structures resulting in enhanced metastatic ability.
Indeed, we have shown that in two colorectal adenocarci-
noma cell lines, the cell line expressing C2-O-sLex, but not
the cell line lacking C2-O-sLex, bound avidly to E-selectin
under shear stress conditions simulating the vasculature
[43]. Importantly, sLex can terminally decorate other cell
surface macromolecules that may not be high affinity
selectin ligands including proteins containing N-glycans,
non-core 2 O-glycans, and glycolipids. Recently, CHO-
131 mAb was found to stain a subset of cutaneous lym-
phocyte-associated antigen (CLA) T cells. P-selectin bind-
ing activity was significantly greater for CHO-131+ CLA+ T
cells than for CHO-131- CLA+ T cells. C2-O-sLex expres-
sion in CLA+ T cells appears to differentially regulate high
affinity binding to P-selectin [58]. In colorectal adenocar-
cinomas, differences in C2-O-sLex expression may simi-
larly regulate adhesion to the selectins and metastasis.
Sialylated Lewis structures such as sLex and sLea are highly
expressed on melanomas and various types of carcinomas
including colon, gastric, pancreatic, squamous cell, and
breast and expression levels correlate with an advanced
stage of disease and poor patient prognosis [2-7,10,59-
Moderately differentiated human colorectal adenocarcino- mas expressed high levels of C2-O-sLex Figure 4
Moderately differentiated human colorectal adeno-
carcinomas expressed high levels of C2-O-sLex. (A) A 
graph of the number of neoplastic cells in well, moderately, 
and poorly differentiated colorectal adenocarcinomas that 
were positive for expression of CHO-131 mAb at low (0+ to 
1+ staining intensity) and high (2+ to 3+ staining intensity) 
levels. (B) A graph of the percentage of colorectal adenocar-
cinomas that were highly positive for C2-O-sLex compared 
to sLex; n = 22, n = 83, and n = 8 for well, moderately, and 
poorly differentiated colorectal adenocarcinomas stained 
with CHO-131 mAb that detected C2-O-sLex; n = 11, n = 
112, and n = 11 for well, moderately, and poorly differenti-
ated colorectal adenocarcinomas stained with CSLEX1 mAb 
that detected sLex. *Moderately differentiated colorectal 
adenocarcinomas expressed significantly higher levels of C2-
O-sLex than well differentiated carcinomas by the Pearson's 
chi-squared test, p = 0.04.
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62]. Moreover, sLex is a selectin ligand capable of mediat-
ing the binding of tumor cells to endothelia, platelets, and
neutrophils [25,28]. It is intriguing to speculate that C2-
O-sLex in some instances is the moiety mediating these
reported interactions. In particular, C2-O-sLex has recently
been shown to be expressed on cutaneous T cell lympho-
mas and is a ligand for P- and E-selectin [63]. We report
here that in colorectal adenocarcinomas and metastatic
liver tumors, C2-O-sLex expression was present in similar
regions of tissue as that noted for sLex expression but the
latter was more widely distributed. This result was
expected because CSLEX1 mAb recognizes the sLex
epitope alone that can be present on several types of gly-
can structures including core 2 O-glycans [64]. In contrast,
CHO-131 mAb specifically detects sLex on core 2 O-gly-
cans which represents a unique subset of glycoproteins
present on tumor cells.
The development of metastasis is an important factor in
determining the outcome of patients with colorectal ade-
nocarcinomas. Metastatic involvement of lymph nodes or
metastases into distant organs greatly decreases the
median patient survival [65]. The liver is the primary site
of metastasis for colorectal adenocarcinomas [66]. Inter-
estingly, sLex expression by carcinomas has been proposed
to enhance the ability of tumor cells to metastasize to the
liver through E-selectin mediated interactions
[3,27,32,67] and sLex epitopes are overexpressed in liver
metastases of colorectal adenocarcinomas [3,8,68]. In our
study, all normal liver tissues lacked reactivity with the
CHO-131 mAb. We found that 87% (40 of 46) of liver
metastases of primary colorectal adenocarcinomas exam-
ined stained positively with the CHO-131 mAb. A subset
(35 of 40) of these positive tissues exhibited high (2+ to
3+) staining intensity with CHO-131 mAb indicating that
C2-O-sLex  was abundantly present on metastatic liver
tumors. Of note is that liver metastases of primary color-
ectal adenocarcinomas but not normal liver tissues
expressed C2-O-sLex. Our findings suggest that high levels
of the C2-O-sLex antigen was preserved on the surface of
colorectal adenocarcinomas cells as they migrated from
the primary tumor to the liver, a common site of metasta-
sis. We speculate that C2-O-sLex expression may be specif-
ically upregulated during metastasis to promote the
metastatic ability of colorectal adenocarcinomas.
Table 2: C2-O-sLex was expressed in colorectal adenocarcinomas metastatic to the liver.
Differentiation status CHO-131 mAb staining reactivity in metastatic liver tumors
0+ 1+ 2+ 3+
W e l l  d i f f e r e n t i a t e d 0012
Moderately differentiated 6 5 10 16
P o o r l y  d i f f e r e n t i a t e d 0033
5 normal liver tissues did not stain with CHO-131.
Table 3: C2-O-sLex was compared to sLex expression in primary colorectal adenocarcinomas and metastatic liver tumors.
Differentiation Status
Well differentiated Moderately differentiated Poorly differentiated
Antibody staining reactivity in colorectal 
adenocarcinomas
0+ (NE) 0+ (1+)* NE (NE)
1+ (2+)* 1+ (1+) 1+ (3+)*
2+ (2+) 2+ (3+)* 2+ (3+)*
3+ (3+) 3+ (3+) 3+ (3+)
Antibody staining reactivity in metastatic liver tumors NE (NE) 0+ (0+) NE (NE)
NE (NE) 1+ (2+)* NE (NE)
2+ (2+) 2+ (2+) 2+ (3+)*
3+ (2+) 3+ (3+) 3+ (3+)
Serial sections of individual tissues were stained with CHO-131 mAb that detects C2-O-sLex and CSLEX1 mAb that detects sLex. The numbers in 
the body of the table indicate the intensity of reactivity of a representative single tissue with CHO-131 mAb. The bracketed numbers indicate the 
intensity of reactivity of a serial section of the same tissue with CSLEX1 mAb. NE = not examined. * indicates a difference in reactivity between 
CHO-131 and CSLEX1 mAbs.BMC Cancer 2009, 9:79 http://www.biomedcentral.com/1471-2407/9/79
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In summary, our results demonstrate that C2-O-sLex is
highly expressed in colorectal adenocarcinomas and liver
metastases but not on benign colorectal and liver tissues.
Our observations suggest that upregulation of C2GnT1
gene expression is correlated with increased cell surface
expression of C2-O-sLex. C2-O-sLex is an important high-
affinity glycan ligand for the selectins on leukocytes and
Human primary colorectal adenocarcinomas and metastatic  liver tumors expressed sLex Figure 5
Human primary colorectal adenocarcinomas and 
metastatic liver tumors expressed sLex. (A) Photomi-
crograph of a serial tissue section of the same well differenti-
ated colorectal adenocarcinoma as shown in Figure 2A 
stained with CSLEX1 mAb (15 μg/ml). Brown color indicates 
positive reactivity with the CSLEX1 mAb. The arrow indi-
cates adjacent normal colorectal mucosa that lacks reactivity 
with CSLEX1 mAb, scale bar = 500 μm. (B) A moderately dif-
ferentiated colorectal adenocarcinoma stained with CSLEX1 
mAb. Brown color indicates positive reactivity with CSLEX1 
mAb, scale bar = 100 μm. (C) A serial tissue section of the 
same poorly differentiated colorectal adenocarcinoma as in 
Figure 3B stained with CSLEX1 mAb (15 μg/ml). Brown 
color indicates positive reactivity with CSLEX1 mAb, scale 
bar = 100 μm. (D) A moderately differentiated metastatic 
colorectal adenocarcinoma in liver stained with CSLEX1 
mAb. The cytoplasm of neoplastic cells reacted positively 
with CSLEX1 mAb as indicated by the brown color, scale bar 
= 50 μm. (E) Mucosa of normal colorectal epithelium stained 
with CSLEX1 mAb. Note the absence of brown color, indi-
cating a lack of reactivity with CSLEX1 mAb, scale bar = 100 
μm. (F) Normal liver stained with CSLEX1 mAb. Note the 
absence of brown color, indicating a lack of reactivity with 
the CSLEX1 mAb, scale bar = 100 μm. All tissue sections 
were 4 μm thickness. Figure (A) 20× magnification, (B) and 
(C) 200× magnification, (D) 400× magnification, (E) and (F) 
200× magnification. Mayer's hematoxylin was used as a coun-
terstain. Representative sections from multiple stained tis-
sues are shown.
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Human metastatic liver tumors of primary colorectal adeno- carcinomas expressed C2-O-sLex Figure 6
Human metastatic liver tumors of primary colorec-
tal adenocarcinomas expressed C2-O-sLex. (A) Phot-
omicrograph of a tissue section of metastatic colorectal 
adenocarcinoma tumors in liver stained with hematoxylin 
and eosin, scale bar = 150 μm. (B) A serial section of the 
same tissue as shown in (A), stained with CHO-131 mAb (15 
μg/ml). Red color indicates positive reactivity with the CHO-
131 mAb, scale bar = 150 μm. (C) A different tissue section 
of metastatic colorectal adenocarcinoma in liver stained with 
CHO-131 mAb, scale bar = 100 μm. (D) A higher magnifica-
tion of the same tissue section as in (C), stained with CHO-
131 mAb (15 μg/ml), scale bar = 50 μm. (E) A serial section 
of the same tissue as shown in (C) and (D), stained with CEA 
mAb (1.6 μg/ml) as a positive control. Brown stained cells 
are positive for CEA mAb, scale bar = 100 μm. (F) Normal 
liver stained with CHO-131 mAb (15 μg/ml). Note the 
absence of red color, indicating a lack of reactivity with 
CHO-131 mAb, scale bar = 100 μm. All tissue sections were 
4 μm thickness. Figures (A) and (B) 100× magnification, (C) 
200× magnification, (D) 400× magnification, (E) and (F) 200× 
magnification. Mayer's hematoxylin was used as a counter-
stain for tissues stained with CHO-131 and CEA mAbs. Rep-
resentative sections from multiple stained tissues are shown.
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cutaneous T cell lymphomas [16,17,19,20,63]. Additional
research is needed to determine whether C2-O-sLex is a
higher-affinity selectin binding ligand than sLex and its
function in the progression and metastasis of colorectal
adenocarcinomas.
Conclusion
Our observations indicate that C2-O-sLex is a tumor-asso-
ciated antigen in colorectal adenocarcinomas and meta-
static liver tumors. Furthermore, C2-O-sLex  expression
may represent an early predictor of progression and
metastasis of colorectal adenocarcinomas. C2GnT1 is a
candidate as a novel target for regulation of C2-O-sLex
synthesis and is potentially important therapeutically to
control carcinoma dissemination. We are currently inves-
tigating the role of carcinoma associated C2-O-sLex com-
pared to sLex in adhesion to the selectins, tumor invasion,
and metastasis. We are also examining the usefulness of
C2-O-sLex as a practical prognostic tool to predict the
long-term survival of cancer patients.
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